R&D channel feed

Mer­ck’s Keytru­da com­bo wows again, ac­ing PhI­II over­all sur­vival goal for lung can­cer ear­ly

8 years ago

Google backs $27M launch round for Holy Grail R&D work on two tar­gets: a can­cer vac­cine and a uni­ver­sal flu jab

8 years ago
Financing
Startups

Teva's board slash­es its own com­pen­sa­tion fol­low­ing mas­sive re­struc­tur­ing

8 years ago

The FDA still hates low T drugs — ex­perts bat back a pair of con­tenders

8 years ago

GSK’s long-qui­et can­cer R&D group is ready to make some noise as it mounts a break­out late-stage ef­fort

8 years ago

Ax­o­vant: That pos­i­tive p-val­ue we re­port­ed yes­ter­day? Um, we screwed that up too

8 years ago

On a mis­sion to save Te­va from crip­pling debt, Schultz stands by cost-cut­ting mea­sures, scru­ti­nizes per prod­uct prof­itabil­i­ty

8 years ago
Pharma

Sanofi, Re­gen­eron up the ante on PD-1 I/O pro­gram by a bil­lion dol­lars

8 years ago
Pharma

Te­va inks $200M glob­al li­cens­ing deal with mi­graine ri­val Alder

8 years ago
Pharma

Ax­o­vant shares blast­ed as Vivek Ra­maswamy's pre­mier drug proves worth­less, sec­ond drug miss­es key goal

8 years ago

Pfiz­er is ax­ing its neu­ro­sciences di­vi­sion, lay­ing off 300 and dis­card­ing new drugs

8 years ago
Pharma

Kala Phar­ma shares dam­aged by mixed da­ta from PhI­II dry eye pro­gram

8 years ago

On a roll, Macro­Gen­ics al­lies with Roche on a bis­pe­cif­ic de­vel­op­ment cam­paign

8 years ago
Pharma

Al­ler­gan ax­ing 1,000-plus jobs, prep­ping for a painful on­slaught of Resta­sis knock­offs

8 years ago
Pharma

Pfiz­er dou­bles down on Sang­amo’s zinc fin­ger tech, adding ALS to a mix of gene ther­a­py al­liances

8 years ago
Pharma
Cell/Gene Tx

J&J’s big block­buster hope­ful es­ke­t­a­mine scores high for ma­jor de­pres­sion — but side ef­fects haunt re­sults

8 years ago

De­nied: FDA re­jects Ag­ile's con­tra­cep­tion patch for sec­ond time

8 years ago

Cel­gene shares sink af­ter an­oth­er PhI­II lym­phoma flop and J&J steps up for the late-stage BC­MA race

8 years ago
Pharma

J&J wows with a $350M cash deal to part­ner on CAR-T with Leg­end, a one-time un­known un­til its star turn at AS­CO

8 years ago
Pharma

Look­ing for an ear­ly suc­cess in PhII Alzheimer’s study, Bio­gen and Ei­sai just racked up the lat­est set­back

8 years ago

An­oth­er death mars Ab­b­Vie's lat­est batch of promis­ing da­ta for its star rheuma­toid arthri­tis drug

8 years ago

GAO re­port tracks the growth of an $89B drug R&D sec­tor as bio­phar­ma sales soared

8 years ago

With AveX­is com­ing up in the rear view mir­ror, Bio­gen and Io­n­is go back to the draw­ing board on SMA

8 years ago
Pharma

Ar­ray joins Pfiz­er on an­ti-can­cer com­bos, the lat­est in a string of binime­tinib com­bi­na­tions

8 years ago
Pharma
First page Previous page 282283284285286287288 Next page Last page
A service from the Financial Times